Our short, quick and targeted approach mixes qualitative and quantitative analysis. By applying market data, history, science and quantitative methods; we synthesize metrics of pricing the RegMed universe. RMI incorporates market dynamics, answering crucial questions and generating actionable investment recommendations.
Understanding and knowing the answer as the release is issued requires a historical knowledge of sector pricing to more than “questimate” share perception and rebounds.
March 2, 2017
Juno Therapeutics (JUNO) another lethal setback for CAR-T program
February 10, 2017
Biostage (BSTG) offering of 20 M common and 100% warrant coverage at $0.40
February 9, 2017
BioTime (NYSEMKT: BTX) Proposes offering of 6.48 M shares at $2.70
February 9, 2017
RegMed Investors’ (RMi) mid-day analysis, momentum has a short fuse
February 8, 2017
RegMed Investors’ (RMi) mid-day analysis, the sector’s floor is cracking
February 7, 2017
RegMed Investors’ (RMi) mid-day analysis, a fast walk to the upside
January 31, 2017
Bellicum Pharmaceutics (BLCM) new CEO
January 28, 2017
Can you afford to miss the insider view
January 26, 2017
Athersys (ATHX) prices offering at $1.01 and is DOWN -$0.48 in the pre-market
January 26, 2017
RegMed Investors’ (RMi) mid-day analysis, pricing is jockeying
January 24, 2017
RegMed Investors’ (RMi) mid-day analysis, slam, bam and no thank you
January 19, 2017
Stemline Therapeutics (STML) proposes 4.5 M share $45 M offering, priced at $10.00
January 18, 2017
Pluristem (PSTI) upsizes share offering to 12.22 M shares with 50% warrant coverage priced at $1.225
January 12, 2017
Histogenics (HSGX) Jumps 40.79% in pre-market
January 11, 2017
RegMed Investors’ (RMi) mid-day analysis, stocks stumble in minutes
January 11, 2017
Sangamo Therapeutics (SGMO) orphan drug designation to SB-318
January 9, 2017
Aduro Biotech (ADRO) Clinical Collaboration with Merck (MRK) - BUY
January 5, 2017
Cesca Therapeutics receives (KOOL) FDA approval for significant revisions to its pivotal study?
January 5, 2017
Fate Therapeutics (FATE) First Patient Treated in ProTmune™ PROTECT Clinical Trial
January 5, 2017
Sangamo BioSciences (SGMO) FDA Clears IND Application
January 5, 2017
Fibrocell Science (FCSC) FDA Fast Track Designation of FCX-007
January 4, 2017
Spark Therapeutics (ONCE) $15 M milestone payment from Pfizer (PFE)
January 3, 2017
Kite Pharma (KITE) submits an IND to initiate a P1 trial of KITE-718 and jumps +2.34%
December 20, 2016
Northwest Bio (NWBO) another 28.6 M share RDO priced at $0.35 and 50% warrant coverage for proceeds of $10 M
4 hours 8 min ago
RegMed Investors (RMi) Closing Bell: Staring into the abyss
12 hours 40 min ago
RegMed Investors’ (RMi) pre-open: What’s next …
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors